ELYM: Eliem Therapeutics, Inc. Market Capitalization-to-Revenue Ratio
Eliem Therapeutics bases its strategy on the search for safe therapies for depression and pain. The price-to-sales ratio on the GURU.Markets chart demonstrates a sideways trend, where serves as the final level mark. This supports partnerships with scientific centers for the development of neuro-drugs and the expansion of the pipeline in the neuroimmunology segment following an asset update.
Metric breakdowns and analytics for eliemtx.com (ELYM)
- stock quotes and analyst forecast:
- market capitalization information:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Eliem Therapeutics|ELYM - Long-Term Debt to Equity|Current Liabilities to Equity Eliem Therapeutics Inc.|ELYM - Company Aggregate Debts|Debts to Book Value Eliem Therapeutics Inc.|ELYM - Company Long-Term Liabilities|Company Short-Term Debts Eliem Therapeutics|Intermediate Liquidity Ratio eliemtx.com
- earnings and multiples data:
ELYM - Net Profit|Company Profit Forecast Eliem Therapeutics|ELYM - P/E Multiple|Projected Price to Earnings Eliem Therapeutics, Inc.|ELYM - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Eliem Therapeutics Inc.|ELYM - Operating profit EBITDA|Net earnings per one share for the last twelve months Eliem Therapeutics|ELYM - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months eliemtx.com|ELYM - Net earnings per share growth this year|Expected net earnings per share growth next year Eliem Therapeutics
- total revenue and sales volume data:
General company analysis:ELYM - eliemtx.com
The P/S multiple compares the market value of Eliem Therapeutics (ELYM) to its operating revenues, determining the value of each unit of revenue in the eyes of investors. For the biotechnology sector, which depends on regulatory approvals for neurological drugs, changes in the price-to-sales ratio serve as an indicator of speculative expectations, allowing a distinction between fundamental business growth and the temporary influence of market sentiment on share prices.
Who Eliem Therapeutics competes with
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (Athira Pharma Inc)|ADXN: P/S Multiple|Market Cap to Revenue Ratio ALZN|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|PTIX (Protagenic Therapeutics) - Market Cap to Sales Volume|P/S Multiple KTTA|Price-to-Revenue Coefficient Cortigent|P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Revenue Ratio|Cara Therapeutics Inc. - P/S Multiple|Chromocell Therapeutics (CHRO) - Market Cap to Revenue|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
